Document is current
Any future updates will be listed below
-
Authors
Vázquez-García, Ignacio https://orcid.org/0000-0003-0427-2639
Uhlitz, Florian
Ceglia, Nicholas
Lim, Jamie L. P.
Wu, Michelle https://orcid.org/0000-0001-6889-8345
Mohibullah, Neeman
Niyazov, Juliana
Ruiz, Arvin Eric B.
Boehm, Kevin M. https://orcid.org/0000-0003-2426-5436
Bojilova, Viktoria
Fong, Christopher J.
Funnell, Tyler https://orcid.org/0000-0003-1612-5644
Grewal, Diljot
Havasov, Eliyahu
Leung, Samantha
Pasha, Arfath
Patel, Druv M. https://orcid.org/0000-0002-5596-4961
Pourmaleki, Maryam
Rusk, Nicole https://orcid.org/0000-0003-2663-6288
Shi, Hongyu
Vanguri, Rami
Williams, Marc J. https://orcid.org/0000-0001-5524-4174
Zhang, Allen W.
Broach, Vance
Chi, Dennis S.
Da Cruz Paula, Arnaud
Gardner, Ginger J.
Kim, Sarah H.
Lennon, Matthew https://orcid.org/0000-0002-1956-6106
Long Roche, Kara
Sonoda, Yukio
Zivanovic, Oliver
Kundra, Ritika https://orcid.org/0000-0001-6723-2859
Viale, Agnes
Derakhshan, Fatemeh N.
Geneslaw, Luke
Issa Bhaloo, Shirin
Maroldi, Ana
Nunez, Rahelly
Pareja, Fresia https://orcid.org/0000-0003-3748-8049
Stylianou, Anthe
Vahdatinia, Mahsa
Bykov, Yonina
Grisham, Rachel N.
Liu, Ying L. https://orcid.org/0000-0001-5790-851X
Lakhman, Yulia
Nikolovski, Ines
Kelly, Daniel
Gao, Jianjiong
Schietinger, Andrea https://orcid.org/0000-0003-3644-1687
Hollmann, Travis J. https://orcid.org/0000-0003-1599-0433
Bakhoum, Samuel F.
Soslow, Robert A.
Ellenson, Lora H.
Abu-Rustum, Nadeem R.
Aghajanian, Carol
Friedman, Claire F.
McPherson, Andrew
Weigelt, Britta https://orcid.org/0000-0001-9927-1270
Zamarin, Dmitriy https://orcid.org/0000-0002-0094-0161
Shah, Sohrab P. https://orcid.org/0000-0001-6402-523X
- License Information
-
More Information
Article History
Received: 20 September 2021
Accepted: 28 October 2022
First Online: 14 December 2022
Competing interests
: S.P.S. is a shareholder of Imagia Canexia Health and a consultant to AstraZeneca, outside the scope of this study. D.Z. reports research funding to MSK from AstraZeneca, Genentech, Synthekine and Plexxikon; personal fees from Synlogic Therapeutics, Hookipa Biotech, Agenus, Synthekine, Memgen, Mana Therapeutics, Tessa Therapeutics and Xencor; and stock options from Accurius, Calidi Biotherapeutics and Immunos. D.Z. is an inventor on a patent concerning the use of Newcastle disease virus as a cancer therapeutic, licensed to Merck. C.F.F. reports research funding to the institution from Merck, AstraZeneca, Genentech/Roche, Bristol Myers Squibb and Daiichi and uncompensated membership of a scientific advisory board for Merck and Genentech and is a consultant for OncLive, Aptitude Health, Bristol Myers Squibb and Seagen, all outside the scope of this manuscript. B.W. reports ad hoc membership of the scientific advisory board of Repare Therapeutics, outside the scope of the submitted work. C.A. reports grants from Clovis, Genentech, AbbVie and AstraZeneca and personal fees from Tesaro, Eisai/Merck, Mersana Therapeutics, Roche/Genentech, Abbvie, AstraZeneca/Merck and Repare Therapeutics, outside the scope of the submitted work. N.R.A.-R. reports grants to MSK from Stryker/Novadaq and GRAIL, outside the scope of the submitted work. D.S.C. is on the medical advisory board of Apyx Medical Co, Verthermia Acquio and Biom'up and is a stockholder of Intuitive Surgical and TransEnterix. R.N.G. reports funding from GSK, Novartis, Mateon Therapeutics, Corcept, Regeneron, Clovis, Context Therapeutics, EMD Serono, MCM Education, OncLive, Aptitude Health and Prime Oncology, outside the scope of this work. Y.L.L. reports research funding from AstraZeneca, GSK/Tesaro and Tesaro Therapeutics outside the scope of this work. Y.L. consults for Calyx Clinical Trials Solutions and holds shares of Y-mAbs Therapeutics. T.J.H. receives research funding from Bristol Myers Squibb, Calico Labs and the Parker Institute for Cancer Immunotherapy. S.F.B. owns equity in, receives compensation from, and serves as a consultant and on the scientific advisory board and board of directors of Volastra Therapeutics. The other authors declare no competing interests.
